Secondary attack rates of SARS-CoV-2 will differ when stratified for the age of the index case.
ID
Bron
Verkorte titel
Aandoening
COVID-19, SARS-CoV-2
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
To estimate secondary attack rates of SARS-CoV-2 and determine factors that impact susceptibility and infectiousness.
Achtergrond van het onderzoek
In December 2019 the first infections of SARS-CoV-2 (COVID-19 disease) were detected in Wuhan, China. The first COVID-19 case in the Netherlands was confirmed on February 27, 2020. In March 2020, the Dutch government mandated a partial lockdown, characterized by social distancing, self-quarantine, closing of schools, bars, and restaurants, and urging people to work from home. As household members live in close contact, the household constitutes a high risk setting for SARS-CoV-2 transmission. The main aims of the present study were to determine the important clinical, epidemiological, virological and immunological characteristics of first COVID-19 cases in the Netherlands and their household contacts. We wanted to estimate secondary attack rates of SARS-CoV-2 and to determine factors that impact susceptibility and infectiousness, stratified by the age of household contacts. We used a dense sampling strategy with sampling from various anatomical sites and by using several molecular and serological diagnostics methods to determine the presence of the SARS-CoV-2 virus.
Doel van het onderzoek
Secondary attack rates of SARS-CoV-2 will differ when stratified for the age of the index case.
Onderzoeksopzet
T1: Home visit within 24 hours after positive test of index case. At this time point we collect questionnaire, serum, naso- and oropharyngeal swabs, saliva and feces.
T2: Home visit 2-3 weeks after inclusion. Data that are collected include questionnaire, serum, swabs, saliva and feces.
T3: Home visit 4-6 weeks after inclusion. Collection of questionnaire, serum, saliva and feces.
T4: Self sampling 6 months after inclusion. Serum by self-sampling (finger prick) and questionnaire.
T5: home visit 9-10 months after inclusion. To collect questionnaire, serum and saliva samples.
Onderzoeksproduct en/of interventie
Not applicable
Publiek
Inge Roof
+31629649396
inge.roof@rivm.nl
Wetenschappelijk
Inge Roof
+31629649396
inge.roof@rivm.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Any person 16 years and older testing positive for SARS-CoV-2 (index case) who had at least one child in their household below the age of 18 and consented to be contacted for scientific research. Every household contact (persons living in the same house as the index patient) was to be enrolled in the study.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Household contacts below the age of 1. Households were excluded if one or more of the household contacts did not want to participate in the study upfront.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL9850 |
CCMO | NL13529.041.06 |
OMON | NL-OMON54806 |